TRIM28 drives immune evasion via PARP1 SUMOylation and NAD <sup>+</sup> depletion in clear cell renal cell carcinoma
This study reveals that TRIM28 is a key regulator of PD-L1 expression and T cell dysfunction in ccRCC through PARP1 stabilization and NAD<sup>+</sup> metabolic reprogramming. Targeting TRIM28/PARP1/PDL1 with Eltrombopag reshapes the immunosuppressive TME and enhances checkpoint blockade efficacy, providing a novel combinatorial strategy for ccRCC immunotherapy.
Authors
- Xiangpeng Zhan (ORCID: https://orcid.org/0000-0001-6872-3705)
- Fu‐Chun Zheng (ORCID: https://orcid.org/0000-0003-3184-3054)
- Songhui Xu (ORCID: https://orcid.org/0000-0003-0269-9129)
- Bin Fu
- Hao Wan (ORCID: https://orcid.org/0000-0002-9990-2359)
- Xingang Cui (ORCID: https://orcid.org/0000-0002-0920-9439)
- Xiaoqiang Liu
- Liu Yang (ORCID: https://orcid.org/0000-0003-0677-6152)
- Jing Xiong
- Luyao Chen (ORCID: https://orcid.org/0000-0003-0469-1681)
- Hongji Hu
Institutions
- Nanchang University (CN)
- XinHua Hospital (CN)
- First Affiliated Hospital of Jiangxi Medical College (CN)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1136/jitc-2025-013025
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China
- Nanchang University
- Health Commission of Jiangxi Province